TRIOCHEM PRODUCTS LIMITED MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS



Regd. Office : 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai - 400 001. Tel. : 00 91 (22) 4082 8100 | Fax : 00 91 (22) 4082 8181 | E-mail : info@amphray.com Corporate Identity Number : L24249MH1972PLC015544

Ref No: TPL PP 0321 2018 29th May, 2018

То

BSE Limited

Corporate Relationship Department,

1st Floor New Trading Ring, Phiroze Jeejeebhoy Towers,

Dalal Street, Fort, Mumbai: 400 001.

Dear Sir / Madam,

Sub: Submission of Audited Financial Results for the Quarter and Year ended 31st March, 2018

Ref: Security Code No. 512101 - ISIN No.: INE331E01013.

We refer to our letter dated 16th May, 2018 on the captioned subject.

In terms of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, In this regard, we wish to inform you that the Board of Director in its meeting held today i.e. Tuesday, May 29, 2018 has considered and approved the Audited Financial Results of the Company for the quarter/year ended 31st March, 2018 duly reviewed by the Audit Committee. The said financial results, duly signed by the Director & CEO of the company along with the statutory auditor's report thereon are enclosed for your perusal and records. A declaration on auditors report with unmodified opinion pursuant to the SEBI Circular no. CIR/CFD/CMD/56/2016 dated May 2, 2016 and notification no. SEBI/LAD-NRO/2016-17/001 dated May 25, 2016 is also enclosed.

Please note that the results are prepared in accordance with Companies (Indian Accounting Standard) Rules 2015 (IND AS), as the Company adopted first time this new accounting standard with effect from April 1, 2017 with transition date of April 1, 2016

Also, informed that the audited financial results in prescribed format will be published in "Free Press Journal" and "Navshakti" newspaper, as required. Please take the same in you record.

Thanking you,

Yours faithfully,

For TRIOCHEM PRODUCTS LIMITED

RAMU S. DEORA DIRECTOR & CEO

mbai



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Regd. Office : 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai - 400 001. Tel. : 00 91 (22) 4082 8100 | Fax : 00 91 (22) 4082 8181 | E-mail : info@amphray.com Corporate Identity Number : L24249MH1972PLC015544

	TRIOCHEM PRODU	CT'S I IMITED			·····		
	Registered Office: Sambava Chambers, 4th Floo		Fost Mumbel	400.001			
	website: www.triocher		Fort, Mumbai	400 001			
	CIN: L24249MH197						
			10 DD 2400 MA				
	AUDITED FINANCIAL RESULTS FOR THE QUART	ER AND TEAR EF	NDED 5151 MA	RCH 2018			
Sr	Particulars		0		(Rs. in lakhs) Except EP		
No	rardculars	21.02.2010	Quarter Ended	· · · · · · · · · · · · · · · · · · ·	Year Ended		
110		31-03-2018	31-12-2017	31-03-2017	31-03-2018	31-03-2017	
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	
		(Refer Note		(Refer Note			
	Income	No. 5)		No. 5)			
	(a) Revenue from Operations	1.0/0.06	(
	(b) Other income	1,249.96	650.38	700.53	3,552.45	1,838.7	
	Total Income from operations	18.64	2.80	4.04	41.02	16.04	
2	Expenses:	1,268.60	653.18	704.56	3,593.47	1,854.82	
	(a) Cost of materials consumed						
	(b) Purchase of stock-in-trade	989.37	294.65	519.29	2,252.41	1,615.82	
	(c) Changes in inventory of finished goods, work-in-progress and stock-in-trade	0.01	43.84	28.50	623.35	55.60	
	(d) Excise duty on sales of goods	-14.22	200.77	71.51	2.23	-153.90	
	(c) Employee benefits expenses		•	25.41	53.40	32.5	
	(f) Finance costs	18.30	18.43	30.82	73.10	67.6	
		3.66	13.45	1.81	38.48	6.2	
	(g) Depreciation and amortisation expense	6.16	6.44	7.89	24.73	27.60	
	(h) Other expenses	56.07	43.42	23.61	168.80	122.3	
	Total Expenses	1,059.35	621.00	708.84	3,236.50	1,774.09	
	Profit / (Loss) from ordinary activities before exceptional items (1-2)						
	Tont / (2005) from ordinary activities before exceptional items (1-2)	209.25	32.18	-4.28	356.97	80.73	
	Exceptional items						
	Profit / (Loss) before tax $(3 + 4)$	-		•	•		
		209.25	32.18	-4.28	356.97	80.73	
-	Tax expense						
	- Current tax						
	- Deferred tax	61.48	10.49	0.28	104.66	28.91	
	Total Tax expenses	-0.89	-1.11	-4.43	-3.19	-5.78	
- F	Profit / (Loss) for the period (5 +/- 6)	60.59	9.38	-4.15	101.47	23.13	
ŀ		148.66	22.80	-0.13	255.50	57.60	
	Other comprehensive income and of income in						
1	Other comprehensive income, net of income tax				[
	A. (i) Items that will be reclassified to profit or Loss	-	-	-	-	-	
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	•	
	B. (i) Items that will not be reclassified to profit or Loss	-0.85	0.16	0.71	-0.38	0.63	
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.22	-0.04	-0.18	0.10	<u>-0</u> .16	
	Total Other comprehensive income, net of income tax	-0.63	0.12	0.53	-0.28	0.47	
Ĥ	Total Comprehensive income for the period (8 +/- 7)	148.03	22.92	0.40	255.22	58.07	
) 1	Paid-up equity share capital (Face value of Rs10/- per share)	24.50	24.50	24.50	24.50	24.50	
	Earning per share (EPS) (of Rs.10/- each) (not annualised)						
I	Basic / Diluted EPS	60.68	9.31	-0.05	104.29	23.51	

റ്റ



2

Factory : Plot No. 10/2, MIDC Industrial Area, Chikhloli, Ambernath (West), Dist. Thane, PIN - 421 505 MAHARASHTRA. Tel. : 0251-268 2191 * 268 2711 | Fax : 0251-268 2192



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Regd. Office : 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai - 400 001. Tel. : 00 91 (22) 4082 8100 | Fax : 00 91 (22) 4082 8181 | E-mail : info@amphray.com Corporate Identity Number : L24249MH1972PLC015544

	STATEMENT OF UNAUDITED ASSETS AND LIABILITY	113 AS AT 5151 MARCH, 2018	
Sr	Particulars		(Rs.in lakh
No	raruculars	As at	As at
110		31-03-2018	31-03-2017
1	ASSETS	Audited	Audited
	Non - Current Assets		
	(a) Property, plant and equipment	132.96	154.3
	(b) Investment property	8.96	9.4
	(c) Other intangible assets	0.02	9.4 0.0
	(d) Financial assets	0.02	0.0
	(i) Other financial assets	7.63	76
i	(e) Other non - current assets		7.6
	Sub total - Non - Current Assets	35.37	40.3
	Current Assets	184.94	211.8
~	(a) Inventories	822.53	010 F
	(b) Financial assets	044.33	219.5
	(i) Trade receivables		244 5
	(ii) Cash and cash equivalents	-	244.5
	(iii) Other financial assets	91.91	40.1
	(c) Other current assets	0.56	0.6
- 1	Sub total - Current Assets	79.93	311.12
- F	Total - Assets	994.93	815.94
ŀ		1,179.87	1,027.80
	EQUITY AND LIABILITIES		
I	EQUITY		
	(a) Equity share capital	24.50	0/ 70
	(b) Other Equity	24.50	24.50
	Total - Equity	778.76	523.54
	LIABILITIES	803.26	548.04
	Non Current Liabilities		
- P	(a) Deferred tax liabilities (Net)		
	Sub total - Non- Current Liabilities	12.92	16.21
	Current liabilities	12.92	16.21
	(a) Financial liabilities		
	i) Borrowings	228.05	285.54
	ii) Trade payables	71.96	152.34
	b) Other current liabilities	0.89	1.37
	c) Provisions	16.22	15.38
	d) Current tax liabilities (Net)	46.57	8.92
	ub- total - Current Liabilities	363.69	463.55
	otal - Liabilities	376.61	479.76
T Tes	otal - Equity and Liabilities	1,179.87	1,027.80

1) The Company operates in single segment only, i.e. chemical and pharmaceuticals.

2) The above results, has been reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on 29th May, 2018 as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3) The Company has adopted Indian Accounting Standards ("Ind AS") which is applicable w.e.f 1st April 2017 and accordingly these financial results have been prepared in accordance with recognition and measurement principles laid down in the Ind AS 34. Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Financial results for the comparative period have also been presented in accordance with the recognition and measurement principles of Ind AS 34. The date of transition to Ind AS is 1st 2016. The Impact of transition has been accounted for in opening reserves. HI ASC

o. 10/2, MIDC Industrial Area, Chikhloli, Ambernath (West), Dist. Thane, PIN - 421 505 MAHARASHTRA MUMB Git 8 2191 * 268 2711 | Fax : 0251-268 2192 Page 2 of 3



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Regd. Office : 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai - 400 001. Tel. : 00 91 (22) 4082 8100 | Fax : 00 91 (22) 4082 8181 | E-mail : info@amphray.com Corporate Identity Number : L24249MH1972PLC015544

4) Corresponding figures of the previous quarter/year have been regrouped, recasted and reclassified to make them comparable wherever necessary. 5) The figure of current quarter and quarter ended 31st March, 2017 / 31st March 2018 are the balancing figures between audited figures of the full financial year ended 31st March, 2018 and 31st March, 2017 (Ind As) respectively and the published year to date Ind AS figures upto third quarter 31st December, 2017 and 31st December, 2016 respectively. 6) The reconciliation of 'Net Profit after tax' and 'Equity' between financial results as per Ind AS and as previously reported under "Previous GAAP' for the quarter and year ended 31st March, 2017 are as under: A. Reconciliation of Net Profit After Tax: Particulars (Rs. in Lakhs) Quarter Ended Year ended 31-Mar-17 31-Mar-17 (Audited) (Audited) (Refer Note No. 5) Net profit as per previous GAAP (Indian GAAP) 0.40 58.63 Add / Less: Increase / (Decrease) in net profit as reported under Indian GAAP Recognition of financial assets at fair value -0.71 -0.76 Reclassification of reimbursement of employee benefits -0.63 Taxes on account of above items 0.18 0.36 Net Profit as per IND AS -0.13 57.60 Other comprehensive income, net of income tax 0.53 0.47 Total Comprehensive income for the period 0.40 58.07 **B.** Equity: Particulars (Rs. in Lakhs) As at 31 Mar 2017 Total Equity (Shareholders' Fund) as per IGAAP 548.04 Adjustments on transition to Ind AS: Total Equity (Shareholders' Fund) as per IND AS 548.04 7) Consequent to introduction of Goods and Service Tax (GST) w.e.f. 1st July, 2017, the Excise Duty / VAT etc. has been subsumed in Goods and Service Tax (GST). In accordance with IND AS 18 on Revenue and Schedule III of the Companies Act, 2013, Revenue from operations are required to be shown net off GST and inclusive of Excise Duty. Accordingly figure of revenue from operation up to the period ended 30th June, 2017 are not comparable with subsequent periods including quarter / year ended 31st March, 2018. FOR TRIOCHEM PRODUCTS LIMITED

Place: Mumbai Lated: 29th May, 2018





RAMU S. DEORA

DIN: 00312369

DIRECTOR

Kanu Doshi Associates LLP Chartered Accountants Mumbai Address : 203, The Summit, Hanuman Road, Western Express Highway, Vile Parle (E), Mumbai - 400 057 T : 022-2615 0100 / 111 / 112 • F : 022 2615 0113

Pune Address : 123, Sohrab Hall, 21 Sassoon Road, Opp. Jehangir Hospital, Pune - 411001 • T : 020 4906 7177 E : info@kdg.co.in • W : www.kdg.co.in

Auditor's Report on quarterly and year to date Financial Results of TRIOCHEM PRODUCTS LIMITED Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Τо,

The Board of Directors of TRIOCHEM PRODUCTS LIMITED

- 1. We have audited the accompanying financial results of **TRIOCHEM PRODUCTS LIMITED** ("Company") for the quarter and year ended March 31, 2018 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
- 2. The quarterly financial results are the derived figures between the audited figures in respect of the year ended 31st March, 2018 and the published year to date figures up to December 31, 2017, being the date of the end of the third quarter of the current financial year, which were subject to limited review.
- 3. This financial results for the quarter ended 31st March, 2018 and year ended 31st March, 2018 have been prepared on the basis of financial results for the nine months ended 31st December, 2017, the audited annual Ind AS Financial Statements as at 31st March, 2018, which are the responsibility of the Company's Management. Our responsibility is to express an opinion on these financial results based on our audit of these financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard ('Ind AS'), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; as applicable and other accounting principles generally accepted in India; our audit of the annual financial statements as at and for the year ended 31st March, 2018.



5

Kanu Doshi Associates LLP

- 4. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.
- 5. In our opinion and to the best of our information and according to the explanations given to us, these quarterly financial results as well as the year to date results:
 - i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 in this regard; and
 - give a true and fair view of the net profit (financial performance including other comprehensive income) and other financial information for the quarter ended 31st March,2018 and for the year ended 31st March, 2018.

6

For KANU DOSHI ASSOCIATES LLP

Chartered Accountants

Firm Registration No: 104746W/W100096

Arati Parmar Partner Membership No: 102888 Place: Mumbai Date: 29th May, 2018



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Regd. Office : 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai - 400 001. Tel. : 00 91 (22) 4082 8100 | Fax : 00 91 (22) 4082 8181 | E-mail : info@amphray.com Corporate Identity Number : L24249MH1972PLC015544

> Ref No: TPL PP 0319 2018 29th May, 2018

То

BSE Limited

Corporate Relationship Department, 1st Floor New Trading Ring, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, <u>Mumbai: 400 001.</u>

Dear Sir / Madam,

Sub: Declaration on Annual Audited Financial Results pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements), Regulation 2015

Ref: Security Code No. 512101 - ISIN No.: INE331E01013.

The Board of Directors of the Company at its meeting held on 29th May, 2018 has approved the Audited Financial Results of the Company for the year ended 31st March, 2018 and we hereby declare that the Statutory Auditors of the Company, M/s. Kanu Doshi Associates LLP., Chartered Accountants, (FRN: 104746W/W100096) have issued an Audit Report with unmodified opinion thereon.

This declaration is issued in compliance with the provisions of the Regulation 33(3)(d) of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended by the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) (Amendment), Regulation 2016 vide notification no. SEBI/LAD-NRO/2016-17/001 dated May 25, 2016 and Circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016,

The Declaration may kindly be taken on your records.

For TRIOCHEM PRODUCTS LIMITED





MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Regd. Office : 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai - 400 001. Tel. : 00 91 (22) 4082 8100 | Fax : 00 91 (22) 4082 8181 | E-mail : info@amphray.com Corporate Identity Number : L24249MH1972PLC015544

TRIOCHEM PRODUCTS LIMITED

Registered Office: Sambava Chambers, 4th Floor, Sir P. M. Road, Fort, Mumbai - 400 001

website: www.triochemproducts.com

CIN: L24249MH1972PLC015544

P-t-	(Rs. in lakhs - except otherwise stated					
	Extract of statement of Audited Financial Results for the Quarter and Year Ended 31st March, 2018					
Sr	Particulars	For the	For the	For the	For the	For the
No		Quarter	Quarter	Quarter	Year Ended	Year Ended
		Ended on	Ended on	Ended on	on	on
		31-Mar-18	31-Dec-17	31-Mar-17	31-Mar-18	31-Mar-17
		Audited	Unaudited	Unaudited	Audited	Audited
1	Total Income from operations	1,268.60	653.18	704.56	3,593.47	1,854.82
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items)	209.25	32.18	-4.28	356.97	80.73
	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items)	209.25	32.18	-4.28	356.97	80.73
	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items)	148.66	22.80	-0.13	255.50	57.60
ĺ	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and other Comprehensive Income (after tax)]	-0.63	0.12	0.53	-0.28	0.47
	Equity share capital (Face value Rs. 10/- per share)	24.50	24.50	24.50	24.50	24.50
7	Other Equity				778.76	523.54
	Earnings per share (of Rs.10/- each) (for continuing and discontinued operations)					
1	a) Basic (not annualized)	60.68	9.31	-0.05	104.29	23.51
1	b) Diluted (not annualized)	60.68	9.31	-0.05	104.29	23.51

Notes

1) The Company operates in single segment only, i.e. chemical and pharmaceuticals.

2) The above results, has been reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on 29th May, 2018 as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3) The Company has adopted Indian Accounting Standards ("Ind AS") which is applicable w.e.f 1st April 2017 and accordingly these financial results have been prepared in accordance with recognition and measurement principles laid down in the Ind AS 34. Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Financial results for the comparative period have also been presented in accordance with the recognition and measurement principles of Ind AS 34. The date of transition to Ind AS is 1st April, 2016. The Impact of transition has been accounted for in opening reserves.

4) Corresponding figures of the previous quarter/year have been regrouped, recasted and reclassified to make them comparable wherever necessary.

8



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Regd. Office : 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai - 400 001. Tel. : 00 91 (22) 4082 8100 | Fax : 00 91 (22) 4082 8181 | E-mail : info@amphray.com Corporate Identity Number : L24249MH1972PLC015544

5	The figure of current quarter and quarter ended 31st March, 2017 / 31st March 2018 are the balancing figures between audited figures of the full financial year ended 31st March, 2018 and 31st March, 2017 (Ind As) respectively.						
6	The reconciliation of 'Net Profit after tax' and 'Equity' between financial results as per Ind AS and as previously						
	reported under "Previous GAAP' for the quarter and year ended 31st March, 2017 are as under: A. Reconciliation of Net Profit After Tax:						
	Particulars						
		(Rs. in Lakhs)					
		For the	For the				
		Quarter Ended on	Year Ended				
		1	on				
		Audited	Audited				
	Net profit as per previous GAAP (Indian GAAP)	31-Mar-17	31-Mar-17				
	Add / Less: Increase / (Decrease) in net profit as reported under Indian GAAP	0.40	58.63				
	- Recognition of financial assets at fair value	0.74					
	- Reclassification of reimbursement of employee benefits	-0.71	-0.76				
	- Taxes on account of above items	-	-0.63				
	Net Profit as per IND AS	0.18	0.36				
	Other comprehensive income, net of income tax	-0.13	57.60				
		0.53	0.47				
	Total Comprehensive income for the period0.4058.07B. Equity:						
	Particulars	~					
			(Rs. in Lakhs)				
	Total Equity (Shareholders' Fund) as per IGAAP	As at 31 Mar 2017					
	Adjustments on transition to Ind AS:		548.04				
			-				
	Total Equity (Shareholders' Fund) as per IND AS 548.04						
,,	Consequent to introduction of Goods and Service Tax (GST) w.e.f. 1st July, 2017, the Excise Duty / VAT etc. has been subsumed in Goods and Service Tax (GST). In accordance with IND AS 18 on Revenue and Schedule III of the Companies Act, 2013, Revenue from operations are required to be shown net off GST and inclusive of Excise Duty. Accordingly figure of revenue from operation up to the period ended 30th June, 2017 are not comparable with subsequent periods including quarter / year ended 31st March, 2018.						
	The above is an extract of the detailed format of financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulation, 2015. The full format of consolidated financial results are available on the Stock Exchange website, www.bseindia.com and on the Company's website						
	www.triochemproducts.com						
	FOR TRIOCHEM PRODUCTS LIMITED						
	SSENI ASSOCI						
		-	0.0001				
	Place: Mumbai		S. DEORA				
	Darect 29th May, 2018		DIRECTOR				
Ϋ́́Λ.	G HOUSE		00312369				
CTORY :	BATTER Plot/Sto 10/2, MIDC Industrial Area, Chikhloli, Ambernath (West), Dist. Thane, PIN - 421 505 MAHARASHT	 RA					
, 625	1268 191 * 268 2711 / Fax : 0251-268 2192 Page 2 of 2						

*